Ensifentrine is Phase III-ready asset targeting a vast market of underserved COPD patients, and company offers one of the best opportunities for investors in the Biotech space. Read full report here on @VeronaPharma by @nplus1singer #shares #stocks
https://t.co/rtbjXQnIvc https://t.co/ldWeq7rj4K